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ABSTRACT
Mulibrey nanism (MUL) is a rare autosomal recessive multi-organ
disorder characterized by severe prenatal-onset growth failure,
infertility, cardiopathy, risk for tumors, fatty liver, and type 2
diabetes. MUL is caused by loss-of-function mutations in TRIM37,
which encodes an E3 ubiquitin ligase belonging to the tripartite motif
(TRIM) protein family and having both peroxisomal and nuclear
localization. We describe a congenic Trim37 knock-out mouse
(Trim37−/−) model for MUL. Trim37−/− mice were viable and had
normal weight development until approximately 12 months of age,
after which they started to manifest increasing problems in wellbeing
and weight loss. Assessment of skeletal parameters with computer
tomography revealed significantly smaller skull size, but no difference
in the lengths of long bones in Trim37−/−mice as compared with wild-
type. Both male and female Trim37−/−mice were infertile, the gonads
showing germ cell aplasia, hilus and Leydig cell hyperplasia and
accumulation of lipids in and around Leydig cells. Male Trim37−/−
mice had elevated levels of follicle-stimulating and luteinizing
hormones, but maintained normal levels of testosterone. Six-
month-old Trim37−/− mice had elevated fasting blood glucose and
low fasting serum insulin levels. At 1.5 years Trim37−/− mice showed
non-compaction cardiomyopathy, hepatomegaly, fatty liver and
various tumors. The amount and morphology of liver peroxisomes
seemed normal in Trim37−/− mice. The most consistently seen
phenotypes in Trim37−/− mice were infertility and the associated
hormonal findings, whereas there was more variability in the other
phenotypes observed. Trim37−/− mice recapitulate several features
of the human MUL disease and thus provide a good model to study
disease pathogenesis related to TRIM37 deficiency, including
infertility, non-alcoholic fatty liver disease, cardiomyopathy and
tumorigenesis.
KEY WORDS: Mulibrey nanism, Infertility, Fatty liver,
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INTRODUCTION
Mulibrey nanism (MUL) is a rare autosomal recessive multi-organ
disorder (OMIM #253250) (Perheentupa et al., 1970, 1973). The
main findings include severe prenatal-onset growth restriction,
cardiac dysfunction due to pericardial and myocardial fibrosis and/
or hypertrophy, infertility, increased risk for tumors, metabolic
syndrome and type 2 diabetes (Eerola et al., 2007; Karlberg et al.,
2004a,b, 2005, 2009a, 2011; Lipsanen-Nyman et al., 2003).
Hepatomegaly and fatty liver are common findings (Karlberg
et al., 2004a, 2005). Most of the patients have a large head relative to
stature and characteristic craniofacial features, including a triangular
face with high, broad forehead, low nasal bridge and scaphocephaly
with occipitofrontal bossing (Karlberg et al., 2004a). A peculiar
high-pitched voice is common in nearly all pre-pubertal children
(Karlberg et al., 2004a). Radiological findings include slender long
bones, J-shaped sella turcica, small thoracic cage and fibrous
dysplasia of the long bones (Karlberg et al., 2004a). Yellowish dots
in the ocular fundi, unequal dispersion of retinal pigment and
hypopigmentation are common ocular findings (Karlberg et al.,
2004a). Some patients present with mild muscular hypotonicity in
childhood and psychomotor development may be delayed, but no
major neurological symptoms are evident (Karlberg et al., 2004a).
Loss-of-function mutations in the tripartite motif-containing 37
(TRIM37) gene underlies MUL with twenty-three different disease-
associated mutations known to date [Avela et al., 2000; Doganc
et al., 2007; Hämäläinen et al., 2004, 2006; Jagiello et al., 2003;
Kallijärvi et al., 2005; Kumpf et al., 2013; the Leiden Open
Variation Database (LOVD; http://databases.lovd.nl/shared/genes/
TRIM37)]. TRIM37 encodes a 108-kDa member of the tripartite
motif (TRIM) protein family that comprises a RING finger, a B-box
motif and a coiled coil domain (Kallijärvi et al., 2005). TRIM37 has
been shown to possess E3 ubiquitin ligase activity and to have both
peroxisomal and nuclear localization (Kallijärvi et al., 2002, 2005,
2006). It has, thus, been proposed to be involved in the peroxisomal
functions of the cell (Kallijärvi et al., 2002, 2005). During mouse
embryogenesis, TRIM37 is widely expressed in the epithelial-
mesenchymal tissues, and in adult mice TRIM37 immunoreactivity
is detected in many neural crest derived tissues. Especially abundant
staining is seen in certain endocrine tissues and in the gonads
(Kallijärvi et al., 2006). In addition to granular cytoplasmicReceived 24 November 2015; Accepted 9 March 2016
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TRIM37 staining, nuclear staining is detected in several tissues
(Kallijärvi et al., 2006). Recently, following a high-content
genome-wide siRNA-based screen to identify genes involved in
regulation of centriole formation in human cells, TRIM37 was
reported to have a role in preventing centriole reduplication events
(Balestra et al., 2013). Moreover, it has been implicated as an
oncogenic histone H2A ubiquitin ligase in breast cancer (Bhatnagar
et al., 2014). However, the physiologic function of TRIM37 and the
disease mechanisms underlying MUL are still unknown.
The mouse Trim37 gene is highly similar to human TRIM37, with
88% identity on mRNA and 92% identity on protein level. We here
describe the generation and detailed characterization of the congenic
Trim37 knock-out (Trim37−/−) mouse strain, which recapitulates
several key features of MUL, thus providing a good model for
studying disease mechanisms associated with TRIM37 deficiency.
RESULTS
Generation and phenotype of Trim37−/−mice
The Trim37 knock-out (Trim37Gt(bgeo)FH, denoted here asTrim37−/−)
mouse strain containing a >16 kb β-geo insertion vector in intron 2 of
the Trim37 gene (see Fig. S1A,B) was generated from BayGenomics
genetrap embryonic stem (ES) cells (see Materials and methods for a
detailed description). Trim37mRNA expression, quantified by qRT-
PCR in the mixed SV129/C57BL Trim37−/− strain, was reduced to
0.7–1.0% in brain (P=0.00014) and to 0.5–3.1% in testis
(P=0.000015) of Trim37−/− compared to wild-type mice (Fig.
S1C). A congenic Trim37−/− mouse strain in C57BL/6JOlaHsd
with wild-type mice of the same background strain as controls were
used in all subsequent experiments.
Trim37−/− mice were viable with no visible abnormalities (fur,
whiskers, eyes, general appearance and behavior normal).
Homozygous Trim37−/− mice were infertile (see below), but in
heterozygous matings, pups were born with normal Mendelian
frequency (Table S1). Early weight development in both sexes was
normal. Male mice started losing weight at the age of 6 months and
females after the age of 12 months (Fig. 1A). In computer
tomography (CT) analysis, six-month-old Trim37−/− mice had
significantly smaller than normal skull size, but no difference in the
lengths of long bones was seen (Fig. 1B,C).
After the age of 12 months approximately one third of mice started
to show increasing problems in well-being, appearing as weight loss
of up to 20%, reduced mobility and changes in behavior. Gross
pathologic examination of these animals revealed hepatomegaly and
fatty liver, splenomegaly, enlargement of pancreas with a granular
appearance, ascites and tumors. The most severe problems appeared
in animals over 18 months of age (see Table S2 for details), which
was set as the latest time point for euthanasia. Extensive behavioral
phenotyping did not show any major differences between Trim37−/−
and control mice (data not shown).
Trim37−/−mice are infertile due to gonadal degeneration
At visual examination both male and female Trim37−/− mice had
normal external genitalia. The mice were mating in a normal manner
as visualized by female plugs after mating, indicating normal
masculinization of Trim37−/− males. Male Trim37−/− mice did
not reproduce at any age (post-natal week 6 onwards). Female
Trim37−/−micewere able to become pregnant at the age of 6 weeks,
but females older than that were infertile.
Trim37−/− males showed histological evidence of testicular
degeneration already at postnatal day 13 (P13) and in adult mice
older than 6 months the testis size was approximately 30% of that in
control mice (Fig. 2A). On histological level the testes of Trim37−/−
mice showed degeneration of germ cells and Leydig cell hyperplasia
starting at P13 with total absence of germ cells being evident in one-
month-old mice (Fig. 2B). Leydig cell hyperplasia in Trim37−/−
mice increased with age (Fig. 2B,C). The testes showed progressive
neutral fat accumulation evaluated as Oil Red O (ORO) staining in
and around Leydig cells from one month onwards (data not shown),
with excessive lipid accumulation present at 18 months (Fig. 2D).
Hormonal measurements demonstrated that four-month-old male
Trim37−/−mice had elevated levels of follicle-stimulating hormone
(FSH; 83.0±12.8 ng/ml in Trim37−/− vs 41.7±17.4 ng/ml in
Fig. 1. Weight and bone parameters in Trim37−/− mice. (A) Weight
development in Trim37−/− and control mice, age 1 to 18 months; mean±s.d.
and group size (n) at given age points 1, 6, 12 and 18 months. M+/+: 15.0±2.9,
n=17; 31.4±3.7, n=16; 38.3±5.0, n=4; 41.7±6.3, n=4; M−/−: 15.1±2.5, n=12;
29.3±2.8, n=15; 32.8±7.9, n=6; 32.5±5.3, n=4; F+/+: 12.6±1.5, n=21;
23.1±2.2, n=14; 29.9±4.1, n=8; 32.5±4.8, n=8; F−/−: 12.3±1.6, n=21;
24.3±2.4, n=15; 28.9±3.3, n=8; 29.4±2.6, n=7. Early weight development of
Trim37−/− mice is normal in both males and females. The males start losing
weight at the age of 6 months and the females at the age of 12 months. (B) CT
scan images of skull and femurs showing the measurement of sagittal (yellow
line) and coronal (green line) skull width and femur length (blue and orange
lines). (C) Skull size of six-month-old Trim37−/− mice is significantly smaller
compared to control mice: sagittal width 9.6±0.1 mm vs 9.8±0.1 ng/ml and
coronal width 13.7±0.2 mm vs 14.0±0.2 mm (mean±s.d.; P=0.01; t-test; n=10/
genotype). No difference in the lengths of humeri, ulnae and femurs could be
detected between Trim37−/− and control mice. M, male; F, female.
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controls; P=0.0014) and elevated levels of luteinizing hormone
(LH; 8.53±2.8 ng/ml in Trim37−/− vs 1.85±2.19 ng/ml in controls;
P=0.007; n=4–6/genotype in both measurements). No difference
was seen in levels of testosterone between Trim37−/− mice
(1.24±0.45 nmol/l) and controls (1.13±0.31 nmol/l; n=5/genotype).
Histological analysis of Trim37−/− ovaries demonstrated germ
cell aplasia and hilus (morphologically similar to Leydig cells of the
testes) cell hyperplasia (Fig. 3A,B). In the developing ovary
primordial follicles and oocytes were present, but already in one-
month-old Trim37−/− mice the number of oocytes was low, when
compared to wild-type controls (Fig. 3A). At the age of six months
female Trim37−/− mice showed absence of germ cells. Some
females also showed ovarian lipid cell hyperplasia (Fig. 3C). In
addition, common ovarian findings in Trim37−/− mice included
cysts and Sertoli cell tumors (Fig. 3B, for more details, see
paragraph ‘Increased incidence of ovarian Sertoli cell tumors in
Trim37−/− females’).
Trim37−/−mice show non-compaction cardiomyopathy
Histological analysis of hematoxylin-eosin (HE)-stained sections of
heart revealed myocardial hypertrabeculation indicative of non-
compaction cardiomyopathy (Fig. 4A). The majority of Trim37−/−
mice had more trabeculated ventricular walls compared to wild-type
controls. Immunohistochemical staining with anti-CD34 showed
the presence of endothelial cells in the trabeculations of the
ventricular wall (Fig. 4B). The weight of heart/total body weight of
Trim37−/− mice did not differ from wild-type controls (data not
shown).
Fig. 2. Testicular findings in Trim37−/− males. (A) Testicles of a 1.5-year-old Trim37−/− mouse and a wild-type littermate. The size of Trim37−/− testicles is
reduced to approximately 30% of that of wild-type mice. (B) HE-stained sections demonstrating degeneration of germ cells and Leydig cell hyperplasia in
Trim37−/−mouse testis, starting at P13. Total germ cell aplasia is evident in one-month-old mice. (C) Adult Trim37−/−mice show total germ cell aplasia and Leydig
cell hyperplasia that is increasing with age. Leydig cells are marked with white arrowheads. (D) ORO stained testicular sections from 1.5-year-old mice, showing
excessive intracellular and intercellular lipid accumulation around the area of Leydig cells in the Trim37−/− mice testis. Scale bars: 20 µm.
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Fatty liver disease and disturbed glucose metabolism in
Trim37−/−mice
Aged Trim37−/− mice (22–24 months) showed a tendency towards
enlarged relative liver size with prominent hepatomegaly (liver
weight 3.0 g and 5.6 g, compared to a mean of 1.5 g in wild-type
mice) in a subset of female mice (Fig. 5A; Fig. S2A). Histological
analysis of HE-stained liver sections in 1-, 4-, 6- and 18-month-old
mice showed progressive vacuolization of the liver (Fig. 5B). One-
month-old Trim37−/− mice and wild-type littermates had similar
liver histology, but at the later age points Trim37−/− mice liver
sections contained increasing amounts of vesicles. The vesicles
were confirmed to have neutral lipid (majority triacylglycerols)
accumulation in droplets by staining with ORO in liver cryosections
(Fig. 5C). The ORO staining data was consistent with the results
from HE-staining with Trim37−/−mice older than 1 month showing
neutral lipid accumulation in liver, with the staining intensity and
lipid droplet size increasing with age. The lipid accumulation was
more prominent in females than in males. Quantitative analysis
of triacylglycerols extracted from liver tissue (n=4–8/group)
(Fig. S2B,C) showed that lipid accumulation in liver started
approximately at the age of 4–6 months and increased with age,
being more prominent in females than in males. The variation in the
content of liver triacylglycerols was high between animals, even
within the same genotype/gender group (Fig. S2B,C).
Analysis of ORO stained cryosections from brain, pancreas,
adrenal gland and ovary did not show any difference in staining
pattern or intensity between Trim37−/− mice and controls (data not
shown). White adipose tissue cell size, determined from images
Fig. 3. Ovarian histology in Trim37−/− females. (A) HE-stained sections demonstrating reduced number of oocytes in ovaries of Trim37−/−mice at P30. Scale
bars: 20 µm. (B) HE-stained sections of ovaries in adult mice showing germ cell aplasia and hilus cell hyperplasia in the Trim37−/−mouse. One cyst (C) is visible in
the 6-month-old Trim37−/− female. Scale bar 100 µm. (C) Some Trim37−/− mice presented with ovarian lipid cell (L) hyperplasia. Scale bars: 20 µm.
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captured from HE-stained paraffin embedded sections, increased
with age, but no difference in cell size was seen between Trim37−/−
mice and wild-type controls (data not shown).
We next assessed the lipid status and several other clinical
parameters in serum samples of six-month-old Trim37−/−
and control male mice after 24-h fasting. Adult six-month-old
Trim37−/− mice had elevated fasting blood glucose levels
(4.71±0.73 mmol/l vs 3.79±0.52 mmol/l; P=0.005) and low
fasting serum insulin values (0.37±0.12 ng/ml vs 0.59±0.33 ng/ml;
P=0.066) compared to wild-type littermates (Table 1). Histological
analysis ofHE-stained pancreatic tissue sections demonstrated similar
amount, size and distribution of pancreatic β-islets in Trim37−/−mice
and controls. No difference was detected in immunohistochemical
staining with an anti-insulin antibody in pancreas (data not shown).
No difference between Trim37−/− and control mice in serum
triacylglycerol, cholesterol, free fatty acids (FFA), long chain fatty
acids, very long chain fatty acids, branched chain fatty acids or the
other assesses parameters were observed (Table 1).
Metabolic phenotyping using the Comprehensive Laboratory
Animal Monitoring System (CLAMS; see Materials and methods
for details) was performed for 30 mice (n=3–4/group; age
20 weeks), fed either standard or fat-enriched Western diet since
weaning. There was no effect of genotype or interaction between
genotype and diet on the measured parameters (Table S3). The only
differences observed were related to the diet, with, as expected, the
mice on high-fat Western diet being heavier than control mice.
However, the mice onWestern diet also showed reduced food intake
(males), reduced water consumption, reduced respiratory exchange
ratio (RER), and lower physical activity (Table S3).
Increased incidenceofovarianSertoli cell tumors inTrim37−/−
females
A gross pathological examination was performed for all Trim37−/−
mice (n=204) and wild-type controls (n=192), 1 to 18 months of
age, dissected during this study (Fig. 6A–E). Histological samples
were collected from all tumors and tissues with abnormal
appearance. Tumors were detected in eighteen Trim37−/− mice
and two wild-type controls (Table 2). With the exception of one
tumor, all were detected in over one-year-old animals and the
majority of them were ovarian tumors of Sertoli cell type (Table 2,
Fig. 6F–H). In addition, there were four individual Trim37−/− mice
with other tumors (Table 2, Fig. 6I–K). Two of the Trim37−/− mice
presented with multiple tumors of the same type in different
locations of the body.
Trim37−/−mice do not display overt peroxisomal pathology
Liver tissue of three-month-old female Trim37−/− mice and wild-
type controls (n=3/genotype) was examined by electron microscopy
(EM) with focus on morphology and distribution of peroxisomes.
Observation of mouse liver electron micrographs gives a cross
estimation over peroxisome abundance. No difference was seen in
the size and shape of peroxisomes between the genotypes, but
Trim37−/− liver contained more lipid droplets that were larger in
size, when compared to control tissue (Fig. S3A).
The response of peroxisomes to a well-known peroxisomal
proliferator, clofibrate, was assessed in groups of four-month-old
male mice fed with a diet containing 0.5% (w/w) clofibrate for two
weeks. Clofibrate is a well-documented lipid lowering drug, which
increases lipoprotein lipase activity and induces peroxisomal
proliferation, by increasing the amount and size of peroxisomes
in the liver of rodents (Lazarow and De Duve, 1976). Peroxisomal
multifunctional enzyme type 1 (MFE-1) is a protein that is highly
inducible by hypolipidemic drugs, which occurs in parallel with
proliferation of peroxisomes. The effect of clofibrate was assessed
by immunoblotting liver lysates with anti-MFE-1 antibody,
(Fig. S3B). The amounts of MFE-1 in the control group (normal
diet) and in mice euthanized immediately after the two-week
feeding period with clofibrate (Cf+0) were similar in both
Fig. 4. Non-compaction cardiomyopathy in
Trim37−/− mice. (A) HE-staining of heart sections
show hypertrabeculation of the heart in six-month-old
Trim37−/− mice. Scale bars: 500 µm. (B) Endothelial
staining (anti-CD34 immunostaining) is present in the
trabeculations of the ventricular wall in Trim37−/− mice
indicative of non-compaction cardiomyopathy
(arrowheads). Scale bars: 20 µm.
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genotypes, suggestive of similar peroxisomal proliferation
(Fig. S3B). No difference was seen in the clearance of MFE-1
after the treatment, as the amount ofMFE-1 was similar in Trim37−/−
and control mice five days after cessation of the clofibrate diet
(Cf+5; Fig. S3B).
Extraction of lipids from livers of the clofibrate treated mice
showed a tendency for Trim37−/− mice to respond in a more
efficient manner to increased lipoprotein lipase activity due to
clofibrate treatment, although no statistical significance was
reached (liver triacylglycerols in Cf+0 groups: Trim37−/− 19.6
±6.3 vs wild-type mice 34.4±5.5; P=0.065) (Fig. S3C). This
findingwas further supported by immunoblotting liver lysates from
clofibrate-treated and control mice with an antibody recognizing
adipose differentiation-related protein (ADRP) (Fig. S3D). ADRP
is a lipid droplet-associated protein, expressed early during
adipocyte differentiation and is a specific marker of lipid
accumulation (Imamura et al., 2002). Quantification of the
ADRP intensities demonstrated that there was a tendency to an
increased lipid lowering response to clofibrate in Trim37−/−
compared to control mice (Fig. S3D).
Finally, in order to investigate if there is a difference in
peroxisomal β-oxidation efficiency we measured the levels of
long chain fatty acids, very long chain fatty acids and branched
chain fatty acids in the sera of the clofibrate treated mice (Table S4).
No differences could be detected between Trim37−/− and wild-type
mice in levels of phytanic acid, docosanoic acid, tetracosanoic acid,
hexacosanoic acid or docosahexaenoic acid. Pristanic acid
values were below detection levels, except in five Trim37−/− mice
(1.5–7.5 ng/ml). Thus, pristanic acid was below the detection level
in all wild-type mice (Fig. S3E).
Fig. 5. Hepatomegaly and fatty liver in
Trim37−/−mice. (A) Enlarged liver and difference
in the liver color in a 22-month-old Trim37−/−
female (F) mouse observed in gross pathological
examination. (B) HE-staining of liver sections
demonstrating sinusoidal dilatation (white
arrowheads) and vacuolization of Trim37−/− liver.
(C) Accumulation of neutral lipids in Trim37−/−
liver visualized by ORO staining. Scale bars:
50 µm.
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The Trim37-deficient mouse model recapitulates several key
features of the multi-organ human disorder Mulibrey nanism,
including infertility, cardiomyopathy, fatty liver and risk of various
tumors (see Table S5 for the approximate frequency of clinical
manifestations in human patients and Trim37−/− mice). Constant
findings that were seen in all Trim37−/− mice were infertility and a
small skull size. The other features were more variable between
mice. Also in MUL patients, organ manifestations differ, especially
in childhood (Karlberg et al., 2004a). Not all patients develop all
symptoms and the severity of the disease varies even between
Finnish patients homozygous for the same mutation (Karlberg et al.,
2004a).
The most consistent phenotypes in human MUL patients are
growth restriction and characteristic craniofacial features (Karlberg
et al., 2004a). The growth restriction is prenatal-onset and there is
incomplete catch-up growth with a final adult height on average of
136 cm in females and 150 cm in males (Karlberg et al., 2007). The
craniofacial features are characterized by a large skull, triangular
face, broad forehead, low nasal bridge and scaphocephaly with
occipital bossing (Karlberg et al., 2004a). In contrast, Trim37−/−
mice showed a decrease in skull size, whereas no changes in the
length of the long bones were detected. This is, however, not
unexpected given that transgenic mice seldom recapitulate growth
restriction phenotypes encountered in human patients. For example
missense mutations in genes involved in fibroblast growth factor
(FGF) signaling in humans lead to various congenital growth
restriction phenotypes, whereas mouse models for these disorders
show normal skeletal phenotypes (Su et al., 2014). Neither could we
in Trim37−/− mice identify structural abnormalities such as fibrous
dysplasia of the long bones, encountered in approximately one
fourth of the human patients (Karlberg et al., 2004a).
Infertility is one of the central phenotypes in human MUL
(Karlberg et al., 2004b, 2011). In male patients infertility is
associated with small testes size, elevated levels of FSH and LH,
low inhibin B and low to normal testosterone levels (Karlberg et al.,
2011). Female patients all develop premature ovarian failure and are
at a high risk of developing ovarian fibrothecomas (Karlberg et al.,
2004b). The infertility phenotype is recapitulated in Trim37−/−
mice. Male mice were not able to reproduce at any age and females
only shortly after puberty. In human MUL patients, however, no
pregnancies have been conceived among the females but one male
patient has fathered a child using assisted reproductive techniques
(Karlberg et al., 2004b, 2011). Based on histological analysis of
human and mouse gonads it is evident that TRIM37 has a critical
role in regulating the maturation of both spermatogenic cells and
oocytes. Both male and female Trim37−/− mice showed early germ
cell degeneration with total aplasia by the age of one month in males
and six months in females, as well as hilus and Leydig cell
hyperplasia, which in male mice was associated with excessive
intracellular and intercellular accumulation of neutral lipids. Ovaries
of Trim37−/− mice also showed lipid cell hyperplasia and increased
incidence of both cysts and Sertoli cell tumors. The hormonal status
in adult male Trim37−/− mice is similar to the human patients
(Karlberg et al., 2011), with high FSH and LH, but normal
testosterone levels. The hormonal data in combination with Leydig
cell hyperplasia imply the presence of compensatory feedback
mechanisms to maintain sufficient Leydig cell function. The
spermatogenic impairment seems therefore not to be caused by
lack of testosterone but rather due to an intrinsic failure of the germ
cells to survive. The increased lipid load in Leydig cells can be a
sign of functional difficulties in Leydig cell steroidogenesis, which
is also reflected by the elevated LH concentration.
The most severe and life-threatening manifestation of human
MUL is the heart disease, manifesting as constrictive pericarditis
and cardiomyopathy with hypertrophy and variable fibrosis
(Lipsanen-Nyman et al., 2003). Histological analysis of mouse
heart revealed cardiomyopathy also in Trim37−/− mice. The heart
tissue showed hypertrabeculation that stained with the endothelial
marker CD34, implying presence of non-compaction
cardiomyopathy similarly to the histopathological findings seen in
some of the human MUL patients (Karlberg et al., 2009a). Non-
compaction of ventricular myocardium (isolated non-compaction
cardiomyopathy of left ventricle) is a cardiomyopathy where the
loosely interwoven fibers of embryonal myocardium fail to
condense normally into solid myocardium leaving in the heart
muscle deep recesses, which communicate freely with the left
ventricle (Ikeda et al., 2015). Positive CD34 staining in the
endomyocardium of Trim37−/− mice verified that these recesses
were true anatomical structures and not artefactual splits, thus
confirming the diagnosis of non-compaction. This is a significant
finding, suggesting that non-compaction cardiomyopathy is an
additional element in the development of the MUL heart disease.
This type of non-compaction cardiomyopathy is still a relatively
poorly defined entity. The consequent heart failure may be due to
abnormal filling and relaxation, as both systolic and diastolic
dysfunction has been described in human patients. The cardiac
phenotype in Trim37−/− mice appears to be mild, as the mice were
viable and survived until adulthood. A subset of mice, however, had
problems in well-being. Even if autopsy in these mice showed
enlargement of liver, spleen and pancreas as well as tumors, the
impact of cardiopathy cannot be excluded. Echocardiography
would be needed to evaluate the contribution of the cardiac
pathology to cardiac function and well-being in Trim37−/− mice.
Liver manifestations are commonly seen in MUL patients. At the
time of diagnosis, approximately half of the patients present with
hepatomegaly and fatty liver is seen in the majority of adults and
adolescents as well as in half of the prepubertal children (Karlberg
et al., 2004a, 2005). In addition, almost half of the MUL patients
develop hepatic peliosis, tumorous lesions comprising blood-filled
Table 1. Serum parameters after a 24-h fast in six-month-old male mice
Trim37−/− Control P-value
Glucose (mmol/l)* 4.71±0.73 3.79±0.52 0.005
Insulin (ng/ml)* 0.37±0.12 0.59±0.33 0.066
ALT (U/l)* 224±131 311±222 0.296
AST (U/l)* 1390±1670 1730±920 0.442
ALP (U/l)* 66.8±59.9 34.4±34.4 0.155
Creatinine (µmol/l)* 33.9±5.1 32.8±3.5 0.572
Total protein content (g/l)* 55.2±4.2 56.9±4.4 0.386
Triacylglycerols (mmol/l)* 0.92±0.20 1.14±0.35 0.098
Cholesterol (mmol/l)* 2.46±0.45 2.72±0.58 0.272
LDH (U/l)* 4090±3140 4830±2530 0.569
Uric acid (µmol/l)* 229±44.3 233±43.2 0.858
FFA (mmol/l)‡ 2.1±0.69 2.2±0.41 0.830
Phytanic acid (ng/ml)‡ 52.0±15.4 40.9±11.3 0.229
C22:0 (ng/ml)‡ 436±75.0 441±80.0 0.928
C24:0 (ng/ml)‡ 396±55.8 391±72.4 0.893
C26:0 (ng/ml)‡ 58.0±8.6 57.5±30.6 0.973
C22:6 (ng/ml)‡ 169,000±22,700 185,000±23,700 0.300
*n=10 and ‡n=5/group. Values are given as mean±s.d. ALT, alanine
transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase;
LDH, lactate dehydrogenase; FFA, free fatty acids; C22:0, docosanoic acid;
C24:0, tetracosanoic acid; C26:0, hexacosanoic acid; C22:6,
docosahexaenoic acid. Total bilirubin and pristanic acid were below detection
levels.
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hepatic sinusoids (Karlberg et al., 2009a). In Trim37−/− mice
hepatomegaly was an infrequent finding by the age of 18 months
and no evidence of hepatic peliosis was observed. However,
progressive vacualization and neutral lipid accumulation in liver
was commonly seen. Triacylglycerol accumulation in liver was
shown to start at the age of 4–6 months and to increase with age,
being, however, highly variable and more prominent in female than
in male Trim37−/− mice. The liver findings in mice are in line with
the observation that deficient TRIM37 function leads to fatty liver
disease.
The most important metabolic finding in MUL is insulin
resistance (Karlberg et al., 2005). While children present with
both low fasting blood glucose and insulin values, more than 90% of
the adult patients show abnormally high fasting insulin levels
Fig. 6. Examples of macroscopic findings in pathological gross examination and tumor histology in Trim37−/− mice. (A) Enlargement of spleen
(arrowhead) in an 18-month-old male (M) mouse. The same mouse had lymphoma of the lymph nodes. (B) Enlarged thymus (arrowhead) in a 14-month-old
female (F) mouse. The tumor was confirmed to be a neuroendocrine carcinoma in histological examination (J). (C) Enlarged pancreas (arrowhead) showing a
granular appearance in an 18-month-old male mouse. In histological examination the pancreatic duct was shown to be cystic, but no tumor formation was present.
(D) Abnormal tissue around the ovary (arrowhead) in a 22-month-old female mouse. In histological examination, the ovary was shown to be hemorrhagic and
necrotic, possibly presenting ovarian torsion. (E) Ovarian tumor (arrowhead) in an 18-month-old female mouse. The tumor was in histological examination
confirmed to be of Sertoli cell type (G). (F–K) HE-staining of tumor sections. Ovarian retiformic Sertoli-cell tumor, female 21 months (F). Ovarian Sertoli cell tumor,
female 18 months (G). Ovarian Sertoli cell tumor, female 14 months (H). Primitive neuroendocrine liver tumor, female 21 months (I). Neuroendocrine carcinoma
of the thymus, female 14 months (J). Lymphoma found in the abdomen, female 15 months (K). Scale bars: 100 µm. M, male; F, female.
Table 2. Tumors detected in Trim37−/− and control mice
Trim37−/− (n=204) Control (n=192)
Ovarian Sertoli (Leydig) cell tumors 14 females (14–22 months) 1 female (18 months)
Primitive neuroendocrine tumor: liver, pancreas, thymus* 1 female (21 months) –
Lymphoma: lymph nodes, ovaries, thymus, distinct tumors in the area of the abdomen* 1 female (15 months) –
Neuroendocrine carcinoma of the thymus 1 female (14 months) –
Lymphoma: lymph nodes 1 male (18 months) –
Hyperplasia or adenoma of the adrenal gland – 1 male (6 months)
*These animals presented with multiple tumors of the same type in different locations of the body.
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resulting in type 2 diabetes in half of the patients (Karlberg et al.,
2005). Trim37−/− mice presented with low fasting serum insulin
values and elevated fasting blood glucose values after a 24-h fast,
implying disturbed glucose metabolism. However, the genetic
background of the Trim37−/−mouse probably contributes to the low
insulin values, as the C57BL/6 mouse strain carries a naturally
occurring deletion in the nicotinamide nucleotide transhydrogenase
gene, which results in impaired insulin secretion (Freeman et al.,
2006) thus possibly overpowering the putative insulin elevating
effects caused by chronic exposure of elevated glucose seen in
human patients. Moreover, a 24-h fast in mice is not entirely
equivalent to human overnight fasting, as it depletes all the
glycogen storages in the liver and provokes a catabolic state in mice
(Ayala et al., 2006). In contrast to human overnight fasting that
impairs insulin stimulated glucose utilization, a prolonged fast in
mice enhances it (Ayala et al., 2006; Heijboer et al., 2005). A
transfer of the Trim37−/− knock-out into another mouse background
strain would be needed to evaluate the glucose and insulin
metabolism, including glucose tolerance tests with insulin
assessment, of Trim37−/− mice without the insulin lowering
effects of the nicotinamide nucleotide transhydrogenase mutation.
MUL patients are at high risk of developing both benign and
malignant tumors (Karlberg et al., 2004a, 2009a). In addition,
disturbed organ development and ectopic tissues are frequent
findings (Karlberg et al., 2009a). The benign tumors include mainly
vascular lesions, cysts, adenomatous and nodular lesions (Karlberg
et al., 2009a), as well as ovarian fibrothecomas (Karlberg et al.,
2009b, 2004b). The main types of malignant tumors includeWilm’s
tumor (Hämäläinen et al., 2006; Karlberg et al., 2004a, 2009a;
Seemanova and Bartsch, 1999; Similä et al., 1980), carcinomas of
different type, acute lymphoblastic leukemia and histiocytosis of
Langerhans cells (Karlberg et al., 2009a). Trim37−/− mice also had
an increased risk of developing tumors, showing a higher frequency
of both benign and malignant tumors than wild-type control
animals. Ovarian tumors of Sertoli cell type were the most frequent
tumor type encountered, with other tumors such as primitive
neuroendocrine tumor, lymphoma and neuroendocrine carcinoma
only occasionally seen. Thus, even if there was a clear difference
in the predominant tumor types between human patients and
Trim37−/− mice our data further strengthens the findings in human
MUL patients that deficient function of TRIM37 is associated with
increased risk of tumorigenesis.
TRIM37 has been suggested to have a peroxisome-associated
function due to its localization to peroxisomes (Kallijärvi et al.,
2002) and due to some overlapping clinical features between MUL
and peroxisomal disorders (Karlberg et al., 2004a). Peroxisomes
are involved in a variety of metabolic processes such as α- and
β-oxidation of long, very long, branched chain and polyunsaturated
fatty acids, as well as biosynthesis of plasmalogens and bile acid
(van den Bosch et al., 1992; Wanders and Waterham, 2006a).
Peroxisomal disorders can be caused by deficiency of single
peroxisomal enzymes (Wanders and Waterham, 2006b) or PEX
gene defects leading to peroxisomal biogenesis disorders (PBDs)
(Steinberg et al., 2006). Here we assessed the role of peroxisomes in
Trim37−/− pathology using different approaches. No obvious
differences in the number, structure or distribution of peroxisomes
in liver tissue between Trim37−/− and control mice were identified.
Moreover, both the proliferation and clearance of the peroxisomal
marker MFE-1 seemed to be similar between Trim37−/− and control
mice upon treatment with clofibrate, a lipid-lowering agent that
increases lipoprotein lipase activity and induces peroxisomal
proliferation. Interestingly, analysis of triacylglycerol content and
ADRP protein amount suggest that Trim37−/−mice may respond to
clofibrate by more efficient lipase activity as in Trim37−/−mice liver
both triacylglycerol and ADRP levels were lower compared to the
wild-type controls immediately after clofibrate treatment. Finally,
no difference was seen in levels of long, very long and branched
chain fatty acids between Trim37−/− and control mice, with the
exception of pristanic acid, which was measurable in a subset of
Trim37−/− mice, the values being below detection level in all
wild-type controls. This could reflect a difference in peroxisomal
β-oxidation efficiency between Trim37−/− and wild-type mice.
Peroxisomal β-oxidation has previously been shown to be essential
for lipid homeostasis and male fertility (Baes and Van Veldhoven,
2012; Huyghe et al., 2006) and would thus be in line with the
identified testicular degeneration and lipid accumulation in
Trim37−/− mice. Of note, deficiencies in peroxisomal function
can result in novel and unexpected phenotypes. For example,
genetic variation in the transcriptional regulation of peroxisomal
and mitochondrial fatty acid oxidation has been reported to
contribute to the development of left ventricular hypertrophy
(Jamshidi et al., 2002). Moreover, the absence of Pxmp2 that is a
channel-forming protein in peroxisomal membrane leads in failure
of mammary gland development in puberty (Vapola et al., 2014).
In summary, the Trim37−/−mouse provides a goodmodel to study
the pathogenetic mechanisms associated with TRIM37 deficiency.
In addition to studies of MUL pathogenesis, this mouse model can
prove insights into the development of infertility, non-alcoholic fatty
liver disease, cardiomyopathy and tumorigenesis. These should be
explored in the light of the recently implied roles of TRIM37 in
centriole biogenesis and histone H2A-associated oncogenesis
(Balestra et al., 2013; Bhatnagar et al., 2014).
MATERIALS AND METHODS
Generation of the Trim37Gt(bgeo)FHmouse strain and genotyping
A BayGenomics genetrap ES cell line with the Trim37 gene trapped
(Trim37Gt(RRO307)Byg; RRO307) was purchased from Mutant Mouse
Regional Resource Centers supported by NIH, MMRRC (UC Davis, CA).
The >16 kb β-geo insertion vector was shown to localize in intron 2 of
Trim37 (Fig. S1A) by polymerase chain reaction (PCR). Chimeric mice
were produced by microinjection of the ES cells to C57BL/6 blastocysts,
which were transferred into SV129 recipient females (Biocenter Oulu,
Transgenic core facility, University of Oulu, Finland). The mixed SV129/
C57BL strain was backcrossed repeatedly (>N9 generations) to C57BL/
6JOlaHsd and congenity of the Trim37Gt(bgeo)FH strain (Trim37−/−) was
verified by SNP genotyping using Mouse Medium Density Linkage Panel
(Illumina, San Diego, CA).
Genotyping of mice was done with one forward primer: IVS2-F7 (5′-
ATCCGTCTGCTGCTTTCCAT-3′) and two reverse primers: IVS2-R7 (5′-
AATGCCACCTGCCTATGTCC-3′) and GT5-R7 (5′-GTTCATATGGT-
GCCGTGCAG-3′) (Fig. S1A-B), which enables simultaneous detection of
the 350 bp wild-type and the 255 bp knock-out alleles. Genotyping of mice
was performed from ear or tail samples by use of standard PCR methods.
Quantitative reverse transcriptase analysis of Trim37−/− and
control mice
Trim37 expression in the mixed SV129/C57BL strain was quantified by
TaqMan reverse transcriptase (RT) PCR (ABI PRISM 7700 Sequence
Detection System, Life Technologies, Carlsbad, CA). RNA was extracted
from brain and testis (n=3/genotype) and converted into cDNA by use of the
High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA).
Amplification was performed with primers 5′-TCAGGAGGTAGAACAT-
CAG-3′ and 5′-GGACAGGTGTGGTGACAAAGGATGC-3′. Probe 6-
FAM-CAGCTCGCTCTTACTGCAAGA-MGB was used for the TaqMan
detection. Normalization of gene expression was performed against
the endogenous control TBP (TATA-box binding protein, Applied
Biosystems).
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All animal experiments were approved by the National Animal Experiment
Board in Finland (licenses ESLH-2006-10696/Ym-23, ESLH-2009-09811/
Ym-23 and ESAVI/6691/04) and performed in accordance with good
practice in laboratory animal handling, following the principles of 3Rs
(replacement, reduction, refinement). The Trim37Gt(bgeo)FH strain was
housed in the Laboratory Animal Center of the University of Helsinki
(license ESLH-2007-05823/Ym-23). The micewere kept in controlled room
temperature and had a 12:12-h light cycle, with free access to standard chow
(Teklad 2916, Harlan Laboratories, Indianapolis, IN) and water. The mice
were inspected daily for changes in behavior or other signs of pain, distress
or disease. Criteria for euthanizing animals were weight loss of 20%,
inability to obtain feed or water, abnormal behavior or movement, signs of
tumors, infection or other disease symptoms. Trim37−/− mice were
monitored for fertility and body weight was measured on a regular basis.
In all experiments gender matched wild-type littermates were used as
controls.
Skeletal assessment with computer tomography
Computer tomography (CT) scans were performed at the Viikki in vivo
imaging unit (http://www.helsinki.fi/cdr/core/nanospect-ct.html), to assess
skeletal parameters in six-month-old mice (n=10/genotype). The CT scan
images were captured with the NanoSPECT-CT device (Bioscan Inc.,
Washington, DC) in mice anesthetized with isoflurane (4% induction, 2%
maintenance). The images were used for measurement of sagittal and
coronal skull size and length of femur, humerus and ulna.
Histology
Brain, heart, lung, liver, pancreas, spleen, intestine, kidney, adrenal gland,
ovary, testis, rib, femur and white adipose tissue, as well as tumors, were
collected frommice at the age of 1, 4, 6 and 18 months. Tissues for one panel,
obtained from mice euthanized by cervical dislocation, were snap frozen in
liquid nitrogen after dissection and stored in −80°C. Tissues for a second
panel were perfusion fixed in mice under terminal anesthesia with
pentobarbital (Mebunat Vet 60 mg/ml, Orion, Finland), followed by cardiac
perfusion with 4% paraformaldehyde (PFA). After dissection the tissues were
post-fixed in 4% PFA and embedded in paraffin. Samples of rib and femur
were decalcified before embedding in 0.5 M ethylenediaminetetraacetic acid
(EDTA), pH7.8 forone and twoweeks, respectively. Paraffin sections of 4 µm
were cut and stored in +4°C prior to staining.
For basic histological analysis of tissues standard HE staining was
performed. Paraffin-embedded sections of heart were stained with the
endothelial marker anti-CD34 (EP373Y, ab81289; Abcam, Cambridge,
UK). The sections were pretreated with Target Retrieval Solution (DAKO,
Glostrup, Denmark) and stained with Novolink Polymer Detection System
(Leica Biosystems, Wetzlar, Germany), using a 1:300 antibody dilution.
Insulin staining of paraffin-embedded sections of pancreas was performed
with 1:800 diluted insulin (C27C9) rabbit mAb (Cell Signaling Technology,
Danvers, MA). Heat-induced antigen retrieval was performed in 10 mM
citrate buffer (pH 6.0). Immunostaining was performed by use of Vectastain
ABC Elite kit (Vector Labs, Burlingame, CA) and SIGMAFAST 3,3′-
diaminobenzidine (Sigma-Aldrich, St. Louis, MO).
For ORO staining 8–10 µm frozen sections of testis, ovary, liver,
pancreas, adrenal gland and brain from mice at the age of 1, 4, 6 and
18 months were cut with the Leica CM3050 S cryotome (Leica
Microsystems, Wetzlar, Germany). Chamber temperature was adjusted
according to the tissue cut; temperatures between −18°C to −20°C were
used. The slides with frozen sections were pre-incubated in 60% isopropanol
and stained for 15 min in ORO (Solvent Red 27; Sigma-Aldrich; 3 mg/ml in
60% isopropanol). Excess ORO stain was removed by dipping the slides in
60% isopropanol and rinsed for 5 min with tap water. Counterstaining was
donewithMayer’s hemalum solution (Merck KGaA, Darmstadt, Germany).
Slides were embedded with glycerol-gelatin (Sigma-Aldrich).
White adipose tissue cell size was estimated from HE-stained paraffin
embedded sections. Light microscope images were captured and analyzed
with Fiji image processing package (http://fiji.sc/Fiji). An area from the
image was measured and divided by the number of cells within. This
resulted in an estimate of cell size for each sample analyzed.
The number of pancreatic islets was estimated visually per low power
field in pancreatic HE-stained sections and in sections immunostained for
insulin. Also the morphology and size of the islets, as well as intensity of
insulin immunostaining were assessed visually.
All histological analyses were done from 2–3 animals per analyzed group.
The pathologist analyzing the histological data did this blinded to the
genotype.
Biochemistry of blood and serum samples
Tail tip and serum samples were collected from six-month-old male mice
after 24-h fasting (n=10/genotype). The animals in the 24-h fasting group
were housed alone and had reversed light-dark cycle for a two-week period
prior to sampling. The mice were euthanized with cervical dislocation and
terminal blood samples were drawn and allowed to coagulate for at least
20 min at room temperature after which serum was separated by
centrifugation (10 min, 2000× g).
Glucosewas measured from the tail tip with the Freestyle lite freedom blood
glucosemonitor (AbbottDiabetesCare Inc.,Alameda,CA). Insulin valueswere
determined from the serum samples with the Ultra Sensitive Mouse Insulin
ELISA kit (Chrystal Chem Inc., Downers Grove, IL). Clinical chemistry
analyses, i.e. measurements of alanine transaminase (ALT), alkaline
phosphatase (ALP), aspartate transaminase (AST), total bilirubin, creatinine,
lactate dehydrogenase (LDH), total protein content, triacylglycerols, cholesterol
and uric acid, were carried out at the Clinical Chemistry Core Facility at the
Institute of Biomedicine, University of Helsinki using the ADVIA 1650
Chemistry System (Siemens AG Healthcare, Erlangen, Germany).
Non-esterified FFAs were determined by use of WAKO NEFA-HR(2)
enzymatic colorimetric assay (Waco Chemicals GmbH, Neuss, Germany).
Long chain fatty acids, very long chain fatty acids and branched chain fatty
acids were determined as fatty acid methyl esters (FAME) by gas
chromatography mass spectrometry (GC-MS) at Metabolomics, VTT
Technical Research Centre of Finland. Serum samples (20 µl) were diluted
with 20 µl of 0.9% sodium chloride, spiked with internal standards
(TG(17:0/17:0/17:0); FFA 17:0) and extracted with chloroform:methanol
(2:1 v/v; 400 µl) containing 0.1% BHT (butylated hydroxytoluene) by
vortexing for 5 min. After 30 min standing, the samples were centrifuged at
10620×g for 5 min and the lower layer was separated and evaporated into
dryness under nitrogen flow. The evaporation residues from lipid extractions
were dissolved into petroleum ether (b.p. 40–60°C; 700 µl). Fatty acids were
transmethylated with sodium methoxide (NaOMe; 0.5 M; 250 µl) in dry
methanol by boiling at 45°C for 5 min. The mixture was acidified with 15%
sodium hydrogen sulphate (NaHSO4; 500 µl) and the petroleum ether phase
containing the FAMEs as well as FFAs was collected. After centrifugation
(10620×g, 5 min) the petroleum ether layer was separated into a GC vial and
evaporated. The residue was dissolved into hexane (50 µl). The samples
(injection volume 1 µl) were analyzed on an Agilent 6890 gas
chromatograph combined with Agilent 5973 mass selective detector
(MSD). A splitless injection method was used and the injector and MSD
interface temperatures were 260°C and 280°C, respectively. The
chromatograph was equipped with a FFAP stationary phase column
(25 m, ID 200 µm, film thickness 0.33 µm; Agilent 19091F-102) and
heliumwas used as carrier gas. FAMEs were monitored at m/z, 284 (C17:0),
312 (pristanic acid), 326 (phytanic acid), 354 (docosanoic acid, C22:0), 382
(tetracosanoic acid, C24:0), 367 (hexacosanoic acid, C26:0), 91 and 273
(docosahexaenoic acid, C22:6), and FFA (C17:0) at m/z 270.
Serum levels of LH and FSH were measured from four-month-old male
mice (n=4–6/genotype) by immunofluorometric assays as described earlier
(Haavisto et al., 1993; van Casteren et al., 2000). The lower limit of LH
detection was 0.75 pg/tube, intra-assay CV <5% at >1 µg/l, and inter-assay
CV 7.8%, while the respective levels for FSH were 0.1 µg/l sensitivity and
4.4% and 10% intra- and inter-assay CV, respectively at a level of 4.8 µg/l.
Serum testosterone (n=5/genotype) was assayed with a radioimmunoassay
(Testo-CT2, Cisbio Bioassay, Codolet, France). Functional detection limit
was 0.3 nmol/l. Intra- and inter-assay CV 8.9 and 11.6%, respectively.
Analysis of liver lipids
Lipids were extracted from frozen liver samples (n=4–8/group) as described
previously (Folch et al., 1957; Siggins et al., 2007). Liver pieces (20–50 mg)
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were homogenized by use of Thermo Savant FastPrep FP120 instrument and
MP Lysing Matrix D tubes (MP Biomedicals, Santa Ana, CA) in 2:1
chloroform:methanol (v/v). The organic phase was washed with 0.9% NaCl
solution and dried under nitrogen. The residuals were dissolved in
tetraethylammoniumhydroxide (1:28 in 95% ethanol) and hydrolyzed
with 0.05 M HCl. Triacylglycerols were measured as glycerol from the end
product by use of an enzymatic colorimetric method (GPO-PAP 1488872,
Roche Diagnostics, Mannheim, Germany).
Electron microscopy
For transmission electron microscopy (EM), female mice (n=3/genotype)
were perfused with 1.0% (w/v) glutaraldehyde in 4% PFA. Liver samples
were cut in 2 mm slices, post-fixed in 1.0% (w/v) osmium-tetroxide,
dehydrated in acetone and embedded in Epon Embed 812 (Electron
Microscopy Science). In mice liver, peroxisomes can be easily recognized
by electron microscopy as particles that are surrounded by single membrane,
that contain electron dense matrix and a highly specific crystalloid structure
named nucleoids.
Metabolic phenotyping with CLAMS
The effect of high fat containing Western diet TD.88137 (Teklad Lab
Animal Diets, Harlan Laboratories, Indianapolis, IN) on metabolic
functions was studied in 30 single housed animals (n=3–4/group, fed
either standard or fat-enriched diet since weaning). At the age of 20 weeks
the mice were tested in the Comprehensive Laboratory Animal Monitoring
System (CLAMS; Columbus Instruments, Columbus, OH) that consists of
eight individual live-in cages that allow automated, non-invasive data
collection of several metabolic parameters, e.g. body weight, oxygen
consumption, carbon dioxide production, RER, heat production,
ambulatory activity and food and water consumption.
During the CLAMS measurements the lights were on between 6:00 and
18:00. The experiment started at 10:00 and continued for 72 h. The period
until beginning of the first dark cycle was allowed for acclimatization. The
data from the following 60 h (3 dark and 2 light periods) were used for
analysis and expressed as mean values per hour during light and dark phase,
respectively. The samples were recorded every 30 min. Body weights were
determined just before and after testing. Two animals were excluded from
the analysis because of losing more than 10% of body weight during the
experiment.
Each cage is an indirect open circuit calorimeter that provides measures of
oxygen consumption and carbon dioxide production. The system compared
oxygen and carbon dioxide gas concentrations by volume at the inlet and
outlet ports of the cage chamber through which ambient air flows at a
constant rate (0.60 l/min). The difference in concentration between the two
ports and the flow information was used to calculate oxygen consumption
(ml/kg/h), carbon dioxide production (ml/kg/h) and RER. Heat production
(kcal/h) was also estimated with standard formulas using oxygen
consumption and the RER. An array of infrared beams (2.5 cm inter-
beam distance) surrounded each cage. Ambulatory activity was defined as a
movement producing sequential horizontal beam breaks of different beams.
Activity was measured continuously and recorded with intervals of one hour
as number of beam breaks. A computer monitored continuously a food
container on an electronic weigh scale. The consumption was monitored and
stored each time a metabolic measure was recorded. Individual water
columns containing pressure transducers supplied drinking water to each
cage. Drinking reduced pressure in the column and was converted to
volume (ml).
Assessment of peroxisomal function
The peroxisomal function in Trim37−/−mice was studied in four-month-old
old male mice fed with a diet containing clofibrate, a peroxisomal
proliferator. Clofibrate [ethyl 2-(4-chlorophenoxy)isobutyrate; Sigma-
Aldrich] was supplemented to the mice with their normal chow
0.5% (w/w). One group of mice (n=3/genotype) was fed for two weeks
with clofibrate and euthanized after treatment. The second group of mice
(n=3/genotype) was euthanized five days after the two-week clofibrate
feeding period. The third group (n=3/genotype) of mice consisted of non-
treated control animals. The animals were euthanized by cervical
dislocation, and serum and liver samples were collected and frozen as
described above.
For immunoblotting frozen liver samples (∼50 mg), from clofibrate fed
and control mice, were homogenized in 50 mM Tris buffer, pH 8.0
containing 0.5% Nonidet-P40, 10% Glycerol, 0.1 mM EDTA and a cocktail
of phosphatase and protease inhibitors. Protein concentrations of the lysates
were determined at A595 nm by use of Bio-Rad protein assay chemistry
(Bio-Rad Laboratories, Hercules, CA).
Samples for the MFE-1 blots were separated on Mini-PROTEAN TGX
Precast Gels (Bio-Rad Laboratories). Immunoblotting was performed using
a 1:2000 dilution ofMFE-1 antibody raised in rabbit (Palosaari et al., 1990),
recognizing the peroxisomal multifunctional enzyme type 1 (MFE-1).
Normalization of protein levels was done against β-tubulin (1:10,000 mouse
anti-β-tubulin, Sigma-Aldrich). Secondary antibodies used were 680
Donkey anti-mouse (Molecular Probes, Eugene, OR) and IRDye 800CW
Goat anti-Rabbit IgG (LI-CORBiosciences, Lincoln, NE). Quantification of
MFE-1 protein from the scanned blots was performed with the LI-COR
Odyssey Western Blot Detection System.
ADRP levels were immunoblotted from liver samples (40 µg of protein per
lane, even loading verified byPonceauA staining of the blottedmembrane) by
using a 1:3000 dilution of anti-ADRP antibodies (Progen Biotechnik GmbH,
Heidelberg, Germany) followed by horseradish peroxidase-conjugated
donkey anti-guinea pig IgG antibodies (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA). The signal was visualized using
enhanced chemiluminescence western blotting detection reagent (ECL)
(Amersham Biosciences, Amersham, UK). Densitometric analysis of the
blots was done with ImageJ software (http://imagej.nih.gov/ij/index.html).
Statistical analysis
Statistical differences between two groups were tested by t-test. All data are
expressed as mean values with standard deviations (s.d.).
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Lehesjoki, A.-E. and Tekin, M. (2007). A novel mutation in TRIM37 is associated
with mulibrey nanism in a Turkish boy. Clin. Dysmorphol. 16, 173-176.
Eerola, A., Pihkala, J. I., Karlberg, N., Lipsanen-Nyman, M. and Jokinen, E.
(2007). Cardiac dysfunction in children with mulibrey nanism. Pediatr. Cardiol. 28,
155-162.
Folch, J., Lees, M. and Sloane Stanley, G. H. (1957). A simple method for the
isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226,
497-509.
Freeman, H. C., Hugill, A., Dear, N. T., Ashcroft, F. M. and Cox, R. D. (2006).
Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus
accounting for glucose intolerance in C57BL/6J mice. Diabetes 55, 2153-2156.
Haavisto, A. M., Pettersson, K., Bergendahl, M., Perheentupa, A., Roser, J. F.
and Huhtaniemi, I. (1993). A supersensitive immunofluorometric assay for rat
luteinizing hormone. Endocrinology 132, 1687-1691.
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